![]() ![]() CC is linked to infection by high-risk human papillomavirus (HPV) genotypes but almost 90% of incident HPV infections are cleared within the two years after initial infection and persist only in 10% of women ( 3– 5). World Health Organization (WHO) estimated that 570 000 new cases are diagnosed per year causing 311 000 deaths in 2018, with 90% of them observed in low-income and middle-income countries ( 1, 2). In biofluids, despite small studies especially concerning miRNAs expression, promising data opens up new avenue to establish a non-invasive signature for lymph node status as well as a tool to predict response to neo- and adjuvant therapies, thus improving management algorithm of patients with CC.Ĭervical cancer (CC) is the fourth cancer in women and is the leading cause of cancer death in 42 countries ( 1). In tissue samples, our analysis found that there are arguments to support the role of ncRNAs in physiopathology, differential diagnosis from normal tissue, preinvasive and invasive tumors. In this review, we aimed to evaluate the contribution of ncRNAs in tissue and biofluid samples to determine lymph node status in CC with potential impact on both surgical and adjuvant therapies. Previous studies have underlined the potential value of ncRNA expression in gynecological cancers. In the specific setting of CC, all data underlined the need for new biomarkers easily available to assess lymph node status. However, assessment of lymph node status remains difficult, despite the progress of imaging such as PET-CT and MRI. Lymph node metastasis is a determinant prognostic factor, as underlined in the latest FIGO classification. 6Gentoyping and Sequencing core facility, iGenSeq, Institut du Cerveau et de la Moelle épinière, Institut du Cerveau et de la Moelle (ICM), Hôpital Pitié-Salpêtrière, Paris, FranceĬervical cancer (CC) is the fourth cancer in women and is the leading cause of cancer death in 42 countries.4Department of Radiology imaging and Interventional speciality imaging, Tenon Hospital, Paris, France.3Sorbonne University, Inserm UMR S 938, Centre de recherche de saint Antoine (CRSA), Hôpital Saint Antoine, Paris, France.2Clinical Research Group (GRC) Paris 6: Centre Expert Endométriose (C3E), Sorbonne University (GRC6 C3E SU), Paris, France.1Sorbonne University, Department of Obstetrics and Reproductive Medicine, Hôpital Tenon, Paris, France. ![]() Yohann Dabi 1,2*, Amelia Favier 1,2, Léo Razakamanantsoa 3,4, Stéphane Suisse 5, Yannick Marie 6, Cyril Touboul 1,2, Clément Ferrier 1,2, Sofiane Bendifallah 1,2 and Emile Daraï 1,2 ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |